Method for reducing the viscosity of purulent airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNase I

ABSTRACT

The invention is generally directed to methods of promoting normal respiratory tract airflow in subjects with restricted airflow and ciliary clearance caused by the presence of pathological airway contents, and particularly mucoid contents. Actin-binding proteins are administered into the respiratory tract of a subject with a pathological respiratory condition involving the presence of such contents. The actin-binding protein binds to actin polymers in the contents and decreases the viscosity. The actin binding proteins also prevent actin from binding to exogenous or endogenous DNase, thus increasing the degradation of DNA polymers in the contents.

This invention was supported by United States Federal Governmentfunding. The government has certain rights in this invention.

This is a division of U.S. application Ser. No. 08/042,247, filed Apr.2, 1993, now U.S. Pat. No. 5,464,817, which is a continuation-in-part ofU.S. application Ser. No. 07/774,738, filed Oct. 10, 1991, and issued onNov. 9, 1993 as U.S. Pat. No. 5,260,224, which is a continuation of U.S.application Ser. No. 07/507,214, filed Apr. 11, 1990, now abandoned.

FIELD OF THE INVENTION

The present invention relates to the treatment of respiratory disordersin which it is desired to disaggregate, depolymerize, or solubilizeactin filaments or to promote the degradation of DNA in respiratorytract mucus. The invention particularly relates to solubilization andincreased clearance of mucus obstructing the respiratory tract in airwaydiseases. The invention relates to a method for reducing the viscosityof mucus by instillation of actin-binding proteins into the respiratorytract. The invention also relates to a method for facilitating theaction of DNase I in respiratory tract treatments by blocking actinbinding to DNase I or reducing the levels of actin in respiratory tractmucus. The method involves the administration of efficacious amounts ofactin-binding compounds, or actin-binding fragments thereof, such thatthe compounds or fragments are active in the respiratory tract of asubject in need of such treatment.

BACKGROUND OF THE INVENTION Airway Obstruction

Airway obstruction caused by inflammatory exudation is a major cause ofmorbidity and mortality. Mucus plugging and stasis is a feature ofchronic bronchitis, asthmatic bronchitis, bacterial bronchopneumoniaand, especially, cystic fibrosis, and is associated with destruction oflung substance. Mucus also contributes to the morbidity of acute andchronic sinusitis and even the common cold.

Mucoid obstruction of the respiratory system is multifactorial. Onefactor is increased mucus synthesis and release caused by inflammatorymediators elicited by infection or irritation. In cystic fibrosis, theviscosity of mucus is increased, presumably because of abnormalepithelial ion transport which affects the hydration or charge of theionic polymers composing the mucus substance. The thick mucus of cysticfibrosis prevents bacterial clearance by ciliary transport and favorsthe growth of bacteria, especially Pseudomonas aeruginosa. Thesebacteria or irritants, such as tobacco smoke generate chemoattractantswhich recruit leukocytes into the airway. As the leukocytes engagebacteria they degenerate, and their components contribute debris thataffect the viscoelasticity of the airway contents.

Much research in the area of pathological mucoid airway contents hasfocused on DNA, since DNA was originally isolated from pus. However,there has also been research on the mucopolysaccharide composition ofmucus and the role of disulfide bonding (Roberts, G. P., Arch. Biochem.Biophys. 173:528-537 (1976); Roberts, G. P., Eur. J. Biochem. 50:265-280(1974); Charman, J., et al., Brit. J. Dis. Chest 68:215 (1974); Bhaskar,K. R., et at., Exp. Lung Res. 10:401-422 (1986); Lethem, M. I., et al.,Eur. Respir. J. 3:19-23 (1990)). Purulent mucus contains about 10-13mg/ml of DNA, an ionic polymer predicted to affect the rheologicproperties of airway fluids. Accordingly, bovine pancreatic DNase I, anenzyme that degrades DNA, was tested as a mucolytic agent many years agobut did not enter clinical practice, because of side effects induced byantigenicity and/or contaminating proteases. Recently, recombinant humanDNase I was tested as a therapeutic agent. The cDNA for human. DNase Iwas cloned and expressed. It was shown to diminish the viscosity ofcystic fibrosis mucus in vitro (Shak, S., et al., Proc. Natl. Acad. Sci.U.S.A. 87:9188-9192 (1990)). Human DNase I has moved beyond phase Itrials and reportedly is effective in improving subjective and possiblyobjective manifestations of purulent airway disease (Aitken, M., et al.,JAMA 267:1947-1951 (1992)).

Extracellular Actin

Actin is the most abundant protein in nucleated animal cells andconstitutes 10-20% of the protein of many nucleated cells and 30% of theprotein of muscle cells. Actin molecules each bind an ATP or ADPmolecule and self-assemble into long filaments during which the ATP ishydrolyzed into ADP.

Injury to animal tissues results in the release of actin into theextracellular space. Although approximately half of nonmuscle cell actinis F-actin, (the double-helical, rodlike, filament form of actin whichis assembled from G-actin monomers), the ionic conditions ofextracellular fluids favor actin polymerization, so that virtually allthe actin released from dying cells would be expected to polymerize intofilaments if sufficiently concentrated (greater than a few microgramsper milliliter) (Lind, S. E. et al., Am. Rev. Respir. Dis. 138:429-434(1988)). Actin polymerizes into long, rod-like filaments which arerelatively resistant to degradation by proteolytic enzymes. In purifiedsolutions, in the absence of filament-shortening proteins, actinfilaments can easily attain lengths of several microns.

Because of the large amounts of actin in cells, the release of actinfrom dying cells provides sufficient actin to have a significant affecton the microenvironment, either by increasing the viscosity ofextracellular fluids, such as mucin, and/or by entrapping cells or byother, as yet unidentified toxic effects. Infusion of extracellular freeactin is toxic to animal tissues (Harper, K. D. et at., Clin. Res.36:625A (1988); Haddad, J. G. et al., Proc. Natl. Acad. Sci. USA87:1381-1385 (1990)). If actin released from injured cells were to bebound to an intracellular actin-binding protein, such as those discussedbelow, this actin would remain monomeric or oligomeric.

Actin-Binding Proteins

There are many proteins which naturally associate with actin. For areview of actin-binding proteins, see Stossel, T. P. et al., Ann. Rev.Cell Biol. 1:353-402 (1985); Pollard, T. D. et al., Ann. Rev. Biochem.55:987-1035 (1986). However, two proteins, gelsolin and DBP (vitamin Dbinding protein) are thought to be primarily responsible for bindingextracellular actin (Janmey, P. A. et at., Blood 70:529-530 (1987)).

Plasma gelsolin (sometimes called brevin) and DBP (also called Gcglobulin) are the two high affinity actin-binding proteins that exist inplasma. High affinity actin-binding proteins bind actin with a K_(d) ofless than 10⁻⁸. Both gelsolin and DBP bind to actin in blood serum andhave actin depolymerizing activity. DBP preferentially binds monomericactin while gelsolin preferentially binds actin filaments.

Gelsolin is a multifunctional actin-binding protein obtained frommammalian cytoplasm and extracellular fluids. Plasma gelsolin differsfrom cellular gelsolin by an additional 25 amino acids at the aminoterminus of the molecule. Both gelsolins are the products of a singlegene. Plasma gelsolin has three actin-binding sites and binds with highaffinity to either G-actin or F-actin.

Plasma gelsolin binds a second actin molecule with a higher affinitythan it binds a first actin molecule. Thus, it preferentially forms 2:1complexes over 1:1 complexes and binds filaments in preference tomonomers. When added to F-actin, plasma gelsolin severs the filament ina nonproteolytic manner and remains bound to one end of the newly formedfilament. If free gelsolin molecules are present, they will sever theactin filament successively until only 2:1 actin-gelsolin complexes arepresent, thereby rapidly depolymerizing the filament.

Free and complexed (to actin) gelsolin molecules differ in theirfunctional properties. Although free gelsolin can sever actin filaments,actin-gelsolin complexes cannot.

Gelsolin's primary function in the plasma and other extracellular fluidsis to sever actin filaments. If gelsolin is present in excess of actin,only gelsolin-actin complexes result; if actin is in excess, there arefree actin oligomers and gelsolin-actin complexes. The actin severingoccurs by way of a nonproteolytic cleavage of the noncovalent bondbetween adjacent actin molecules. Gelsolin's severing activity isactivated by micromolar Ca⁺⁺ and by pH above 6, and has been shown to beinhibited by phosphatidyl inositol 4-5-bisphosphate (PIP₂) andphosphatidyl inositol-4-monophosphate (PIP). Since extracellular Ca⁺⁺concentrations are at millimolar levels and extracellular fluids do notnormally contain PIP or PIP₂ in a form that inhibits gelsolin, plasmagelsolin is constitutively active in extracellular fluids.

Human extracellular (plasma) gelsolin cDNA has been cloned and sequenced(Kwiatkowski, D. J. et al., Nature 323:455-458 (1986); Kwiatkowski, D.J. et al., J. Cell Biol. 106:375-384 (1988)). Fragments of the nativeprotein which retain the ability to bind actin have been identified(Bryan, J., J. Cell Biol. 106:1553-1562 (1988); Yin, H. L. et al., J.Cell Biol. 107:465a (1988), abst. no. 2616); Kwiatkowski, D. J. et al.,J. Cell Biol. 108:1717-1726 (1989); Way, M. et al., J. Cell Biol.109:593-605 (1989)). There is no evidence to suggest that it isgenetically polymorphic (except in the uncommon genetic disorder calledFinnish-type amyloidosis in which single amino acid mutations are foundin plasma gelsolins), indicating that use of recombinant human proteinshould not lead to immunogenic or other toxic effects. Plasma gelsolinhas been detected in many body fluids, suggesting that gelsolin may be anormal component of airway fluid, at least in states of inflammation.

DBP has also been cloned (Cooke, N. E. et al., J. Clin. Invest.76:2420-2424 (1985); Yang, F. et al., Proc. Natl. Acad. Sci. USA82:7994-7998 (1985)). DBP has a single actin binding site and bindsconstitutively to monomeric but not F-actin.

Actin and DNase I

The catalytic activity of DNase I is inhibited by actin, to which theenzyme binds tightly (Lindberg, U., Biochem. Biophys. Acta 82:237-248(1964); Lazarides and Lindberg, Proc. Natl. Acad. Sci. USA 71:4742-4746(1974)). In addition, DNase I, by ligating actin subunits, candepolymerize actin filaments. This background suggested that DNase Imay, in addition to degrading DNA, depolymerize actin in airwaysecretions.

Actin comprises about 10% of the protein mass of leukocytes. It follows,therefore, that abundant actin, as well as DNA polymers, might exist inpurulent airway contents. If actin does exist in these contents, theefficacy of DNase I in DNA degradation would predictably be reduced bybinding to actin present in the very secretions for which DNase I wasintended.

Actin filaments alone produce networks of high elasticity, and wheninterpenetrated within mucus and/or DNA polymers, predictably wouldcontribute to very rigid gels as they do with fibrin (Janmey, P. A.,Blood 80:928-936 (1992)). Introduction of actin-binding molecules thatdisaggregate actin filaments, especially by severing actin filaments(Janmey, P. A., Curr. Opinion Cell Biology 3:4-11 (1991)) is thereforean attractive approach to reducing the consistency of airway mucus, andespecially purulent airway mucus.

Since actin inhibits the catalytic activity of DNase I, actin-bindingmolecules should also enhance the efficacy of DNase I in degrading DNAby solubilizing actin and facilitating its removal from DNA-containingairway mucus in which DNase I is intended to be effective.

SUMMARY OF THE INVENTION

The present invention is based upon the Applicants' consideration that,since leukocytes are a significant component of purulent mucus and actincomprises about 10% of the protein mass of leukocytes, abundant actinmight exist in purulent mucoid airway contents. The invention is alsobased on the consideration that the efficacy of DNase I in degrading theDNA polymers in purulent mucus would predictably be reduced by bindingto actin present in the mucus. Therefore, the effect of both endogenousDNase I and DNase I added for therapeutic purposes would be reduced bybinding to actin present in the very secretions for which the enzymeswere intended.

Accordingly, the present invention is based upon the Applicant'sconsideration that the administration of actin-binding compounds, orbiologically active derivatives thereof, to subjects with pathologicalmucoid airway contents will provide treatment of and protection againstobstruction of the respiratory tract. It is therefore an object of theinvention to provide a method for depolymerizing actin filaments,preventing actin polymerization, and for decreasing the levels of actinin the respiratory tract of individuals with airway disease.

It is an object of the invention to provide a method for the reductionof viscosity or solubilization of mucoid airway contents, obstructingthe normal patency and flow of air in the respiratory tract inindividuals with airway disease, and especially inflammatory airwaydisease.

Accordingly, the invention provides a method to reduce the viscosity orconsistency of pathological airway contents by instillation into therespiratory tract of actin-binding compounds, and especiallyactin-binding proteins which: 1) disaggregate (depolymerize, fragmentand dissociate) actin filaments released from disrupted leukocytes andother cells that solidify airway contents, and especially mucoid airwaycontents, and/or 2) prevent actin from inhibiting the action of theenzyme DNase I which degrades DNA polymers that increase theviscoelasticity of mucus. The DNase I may be endogenous or supplied fortherapeutic purposes by aerosolization or any other appropriate andeffective means.

Accordingly, a further object of the invention is reducing the level ofactin binding to DNase I in the respiratory tract by the administrationof actin binding compounds, and especially actin-binding proteins, tothe respiratory tract. A further object of the invention is to enhanceDNA degradation in pathological mucoid airway contents by theadministration of actin binding compounds, and especially actin-bindingproteins.

These and other objects of the invention, which will hereinafter becomemore readily apparent, have been obtained by administering to subjectswith mucoid airway contents causing airway obstruction, one or moreactin-binding proteins or active fragments thereof, in doses and under aregimen that treat the obstruction which occurs after actin and/or DNArelease into said contents.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1. Dynamic shear moduli of cystic fibrosis sputum. Sputum sampleswith or without gelsolin or gelsolin fragment were placed between theparallel circular plates of a torsion pendulum (Ferry, J. D.Viscoelastic Properties of Polymers, 3rd Ed., John Wiley & Sons, NewYork (1980)) and a momentary displacement was applied to the armattached to the upper sample plate. The dynamic shear modulus, G', wascalculated from the frequency and damping of the resulting freeoscillations. G' of actin polymer-containing solutions depends stronglyon the average actin filament length (Janmey et al., Biochemistry27:8218-8226 (1988)). 1A: Cystic fibrosis sputum alone; 1B: Cysticfibrosis sputum plus gelsolin; 1C: Cystic fibrosis sputum plus gelsolinamino acid fragment 1-260.

FIG. 2. Shear creep and recovery of cystic fibrosis sputum. Sputumsamples with or without gelsolin or gelsolin fragment in between platesof the torsion pendulum were subjected to a constant shear stress. Thesubsequent deformation is quantified as the shear compliance, the ratioof shear strain to the imposed stress. Previous studies have shown thatthe compliance of F-actin increases sharply as the average filamentlength decreases (Janmey et al., Biochemistry 27:8218-8226 (1988)). Theabrupt decreases in strain represent release of the applied stress.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is based on the consideration that airway(respiratory tract) contents may contain actin filaments and DNApolymers which increase the consistency or viscosity of the airwaycontents and, by doing so, prevent normal clearance and lead topathological consequences. Accordingly, an object of the invention is toreduce the consistency of pathological airway contents by causing thedisaggregation or depolymerization of actin filaments, the inhibition ofactin polymerization, reduction of actin levels, and the degradation ofDNA polymers. Accordingly, in one embodiment of the invention, anactin-binding compound or compounds is introduced into the respiratorytract of a subject whose airway contents contain actin filaments and DNApolymers that contribute to respiratory distress. The actin-bindingcompound may disaggregate actin, prevent or reduce the polymerization offree monomeric actin, or prevent the binding of actin filaments ormonomers to DNase I, or both. A general embodiment of the invention is amethod for the solubilization or reduction in consistency or viscosityof pathological respiratory contents in the respiratory tract ofindividuals experiencing respiratory distress as a result of thepresence of such contents.

The present invention is further based upon the consideration thatairway mucus may contain actin filaments and DNA polymers which increasethe consistency or viscosity of this mucus and thus prevent normalairflow and clearance. Accordingly, it is an object of the presentinvention to reduce the viscosity or consistency of such mucus by theadministration, into the respiratory tract Containing such mucus, of anactin-binding compound or compounds. The compound may act bydisaggregating (depolymerizing) actin filaments into actin monomers, bybinding to actin so as to prevent the binding of actin to DNase I, orboth. The compound may also act by preventing the polymerization ofactin monomers into filaments. By promoting mucus clearance, thecompound ultimately can reduce the levels of actin in the airwaycontents. Accordingly, in one embodiment of the invention, a method isprovided for reducing the consistency or viscosity of airway mucus orsolubilizing said mucus, by the introduction of an actin-bindingcompound or compounds into the respiratory tract of an individual whoserespiratory tract contains said mucus.

The present invention is further based upon the consideration thatpurulent mucus in the respiratory tract contains significant leukocytecontamination such that said mucus contains DNA polymers increasing theconsistency or viscosity of said mucus and may contain amounts of actinfilaments such that the mucus contributes to airway obstruction, reducedexpectoration, and other forms of respiratory distress. Accordingly, itis an object of the invention to reduce the consistency of purulentmucus by causing the disaggregation (depolymerization) of actinfilaments that may be present in said mucus and by enhancing thedegradation of DNA polymers present in said mucus. Therefore, in apreferred embodiment of the invention, the consistency or viscosity ofpurulent mucus is reduced by introducing into the respiratory tract ofan individual with said mucus, an actin-binding compound or compounds.The actin-binding compounds may produce their effect by depolymerizingactin into actin monomers, binding to actin filaments and monomers so asto prevent their binding to DNase I, or both. The compound may also actby preventing the polymerization of actin monomers into filaments. Bypromoting mucus clearance, the compound ultimately can reduce the levelsof actin in the airway contents.

In all embodiments of the invention, if DNase I is present, it can beeither endogenous or added exogenously for therapeutic purposes. When itis added for therapeutic purposes, it may be co-administered with theactin-binding compound or separately.

In further embodiments of the invention, biologically active derivativesof the actin-binding compounds are administered to subjects withpathological airway contents, mucus, or purulent mucus in theirrespiratory tracts to protect against obstruction of the respiratorytract or reduction of expectoration.

In all embodiments of the invention, the methods are directed toreducing the consistency of the specific airway contents by instillationinto the respiratory tract of a subject in need of such treatment,actin-binding compounds which may do one or more of the following: (1)disaggregate, depolymerize, fragment, and dissociate actin filamentsreleased from disrupted leukocytes and other cells that solidify airwaycontents (2) prevent actin from inhibiting the action of DNase I whichdegrades DNA polymers by blocking actin binding to DNase I (3)ultimately reduce the level of actin in airway contents by promotingclearance of the contents. It is to be understood that the actin presentin respiratory contents, for the purpose of the invention, isextracellular actin in said contents in free monomer or filament form.

In all embodiments of the invention in which the efficiency of DNase Iis enhanced, the ultimate object of the embodiment is to enhance DNAdegradation in pathological airway contents, and particularly in mucusand purulent mucus.

The diseases that are amenable to treatment by the methods of thepresent invention include, but are not limited to cystic fibrosis,chronic bronchitis, mucopurulent or purulent exacerbation of simplemucoid bronchitis, bronchorrhea, bronchopneumonia, widespreadbronchiolitis, purulent pneumonia, pneumonic-alveolar-consolidation,asthma, with or without asthmatic bronchitis with mucus plugging, acuteand/or chronic purulent sinusitis, empyema, bronchiectasis,bronchocoele, adult respiratory distress syndrome (ARDS),post-transplantation obliterative bronchiolitis, and allergenicbronchiolitis (fibrosing alveolitus).

In a preferred embodiment of the invention, the methods are practicedwith the protein gelsolin or an active fragment thereof. Gelsolin may beinstilled into the respiratory tract by routine methods such as thoseused to administer DNase I to subjects with respiratory distress. Thetreatment is not, however, limited to gelsolin.

In a further embodiment, additional gelsolin can be introduced into theairway by the intravenous route. The embodiment is based on theconsideration that drug delivery by inhalation may be inherently limitedin congested airways because of obstruction. Effective solubilizationcould be expected to enhance drug delivery by inhalation. On the otherhand, an assault from the blood side may deliver the drug into alveolias well as bronchioles and bronchi, such delivery being heightened bychronic inflammation and concomitant increased blood-tissuepermeability.

It is known that plasma proteins can enter the airways as evidenced byα-1-antitrypsin therapy of hereditary emphysema. Presumably efficiencyof blood to tissue delivery is a direct function of blood levels.Gelsolin levels can be measured to determine if airway binding to actinhas had a depleting effect.

Since the major source of plasma gelsolin is muscle, it may be thatlevels fall as patients become increasingly cachectic in response tochronic infection and hypoxia.

It was shown (Am. J. Path. 130:261-267 (1988) and Am. Rev. Resp. Dis.138:429-434 (1988)) that plasma gelsolin levels are depressed inexperimental lung injury and in clinical ARDS, and others have claimedthat there is some relationship between muscle mass and plasma gelsolinconcentrations (Yamamoto, H., Osaka Gas Group Foundation PublicationVolume 5:145-147 (1992)).

In order to provide a clearer and consistent understanding of thespecification and claims, including the scope to be given such terms,the following definitions are provided.

The term "respiratory tract" or "airway" would be understood by theskilled artisan to refer to the tubular and cavernous organs andstructures by means of which pulmonary ventilation and gas exchangebetween ambient air and blood are brought about. This would beunderstood to include, inter alia, the nasal cavity and conchae, thepharyngeal opening of the auditory tube, the pharynx, the larynx, thetrachea, the bronchi, and the lungs. The invention is directed totreatment of airway contents, mucus, purulent mucus, etc. in any of theparts of the tract, particularly sub-tracheal.

It would be understood by the ordinary skilled artisan that "airwaycontents" or "respiratory tract contents" comprise a mixture ofsubstances normally produced by the cells lining the airway (forexample, through secretion) or remnants of the cells themselves.Accordingly, the skilled artisan would understand the term "pathological(mucoid) airway contents" or "pathological (mucoid) contents of therespiratory tract" to refer to those contents that contain componentsleading to structural and functional changes in the airway contentswhich cause abnormal respiratory tract function and/or disease. Theseinclude, but are not limited to, mucus, purulent mucus, thick mucus,such as in cystic fibrosis, bacteria, and the like. The components mayalso be biological components of mucus that alter the properties ofmucus and cause disease or distress. The components themselves may becaused by an underlying disease state that contributes to an increase inthe amount of normal airway contents or a change in the type ofcomponents from the components normally found in airway contents. Forexample, there may be an imbalance or disproportionate amount of certaincomponents normally found in airway contents. By "respiratory distress"is meant the consequences of pathological airway contents which include,but are not limited to, reduced airflow, obstruction of the airway,reduced respiratory clearance by cilia, reduced respiratory clearance bymuscular mechanisms such as coughing, clearing the throat, and sneezing,respiratory irritation from prolonged contact with the contents, theretention of leukocyte-derived lyric enzymes, inflammatory mediators,fungi, mycoplasma, bacteria, or other microorganisms.

By the term "mucus", the ordinary skilled artisan would understand thefree slime of the mucus membranes, composed of secretion of the glands,along with various inorganic salts, desquamated cells, and leukocytes.

By the term "purulent mucus", for the purpose of the present invention,the skilled artisan would understand mucus that is rendered highlyviscous, relatively solidified by DNA polymers derived from white bloodcells and/or desquamated and/or broken endogenous airway cells.

The phrases "solubilizing (mucoid) airway contents", "solubilizingmucus", or "solubilizing purulent mucus" are intended to mean changingthe mechanical properties of said contents, mucus, or purulent mucus soas to render such contents more like a liquid and less like a solid,more compliant, and better able to flow in response to shear stress.Disaggregation of polymers contributing to the viscosity of thesecomponents can also release proteins and other molecules trapped in theinterstices of the contents/mucus/purulent mucus gel. The terms"reducing the viscosity" or "reducing the consistency" would also beunderstood to mean changing the mechanical properties, as describedimmediately above. The term "viscosity" would be understood by theskilled artisan to denote a physical property of a substance that isdependent on the friction of its component molecules as they slide byone another. A highly viscous solution would be characterized by a highdegree of friction between component molecules, whereas a reducedviscosity would be characterized by a decrease in the degree of frictionbetween component molecules as they slide by each other.

By "exogenous DNase" is intended DNase which is added by clinical meansto a subject in need of such DNase by virtue of respiratory distresscaused by DNA polymers in the subject's respiratory tract.

By "endogenous DNase" is intended DNase which is found in therespiratory tract of a subject, and particularly in the mucus of saidsubject's respiratory tract.

By the term "enhance DNA degradation" for the purposes of the presentinvention is intended adding that amount of an actin-binding compoundwhich will bind to actin present in pathological airway contents, mucus,or purulent mucus, which actin, if not exposed to said actin-bindingcompound, would bind to DNase present in these fluids, inhibiting thisDNase from reducing the amount of DNA polymer to allow decreasedviscosity, enhanced respiratory airflow, expectoration, and relief fromother forms of respiratory distress caused by the airway contents.

Actin-Binding Compound.

"Actin-binding compound" is meant to include any compound, andespecially any protein (or peptide), which is capable of binding actinso as to modify any of actin's many functions, including suppressing theability of actin monomers to polymerize into filaments, to fragment(dissaggregate, depolymerize) pre-existing filaments, and to bind toDNase I. When administered to a subject in need of treatment, theactin-binding compounds of the invention are substantially free ofnatural contaminants which associate with such compound either in vivo(in a prokaryotic or eukaryotic) host, or in vitro (as a result of achemical synthesis). Such compounds include, but are not limited toextracellular actin-binding proteins such as gelsolin and DBP, andintracellular act proteins such as those most abundant in cells (forexample, myosins, tropomyosins, profilin and cofilin) and those mostabundant in non-muscle cells. Actin-binding compounds within the scopeof the methods of the invention also include but are not limited to a)actin-binding compounds that predominantly sequester actin monomers,that is, bind monomers in a complex which is resistant to polymerization(for example, DBP, profilin, β₄ -thymosin 1, cofilin, and DNase I); b)actin-binding compounds which sequester monomers and possess filamentsevering activity (for example, gelsolin, villin, fragmin and severin;c) actin-binding compounds that predominantly block the ends of actinfilaments and prevent the exchange of monomers with that end (forexample, tropomodulin, capZ, cap 100, ASP-56); and d) actin-bindingnonproteinaceous molecules that have such effects on actin (for example,cytochalasin or biologically-active derivatives thereof, that block theends of actin filaments and which are modified to remain extracellular).The skilled artisan would understand that useful compounds would remainextracellular in order to prevent any toxicity by interaction withfunctional intracellular actin. Fragments of actin-binding proteins withretained actin filament-severing and/or monomer-sequestering activityare also within the scope of the present invention.

If desired, such compounds may be administered in the form of apharmaceutically acceptable salt to the animal.

Animal.

The term "animal" is meant to include all animals in which free actin oractin filaments in the sputum would be detrimental to the physiology ofthe animal. Foremost among such animals are humans; however, theinvention is not intended to be so limiting, it being within thecontemplation of the present invention to treat any and all animalswhich may experience the beneficial effect of the invention.

Efficacious Amount.

An "efficacious amount" of an actin-binding compound is one which issufficient to reduce or eliminate the toxic effects of actin in therespiratory tract contents of an animal. With respect to the presentinvention, it is the amount of compound effective to solubilize orreduce the viscosity or consistency of pathological airway contents,mucus, or purulent mucus, inhibit actin-binding to DNase I in theseliquids or gels, enhance DNA degradation in these liquids or gels, orreduce the consistency of these liquids or gels so as to treat variousforms of respiratory distress. An efficacious amount of an actin-bindingcompound is also that amount which may reduce bacterial content, theincidence of clinical infection, reduce the content of inflammatorymediators, or the content of degradative and cytotoxic enzymes inrespiratory distress syndromes causing or caused by these liquids orgels.

The amount of the actin-binding molecule to be given, and the durationof therapy, may be determined by monitoring the frequency ofexacerbation of symptoms or the deterioration of symptoms, the sputumvolume and consistency, the pulmonary functions such as FEV, blood pO₂,pH, pCO₂, total lung capacity, residual volume tests of air flow,infection rate, etc. The skilled clinician would be familiar withroutine monitoring techniques for respiratory treatment.

The amount of aerosolized actin-binding protein may be determinedaccording to those procedures used to determine the doses of DNaseinhalation effective for treatment of patients with DNase I. Forexample, see Aitken, M. L., et at., J. Am. Med. Assoc. 267:1947-1951(1992), particularly page 1948, "Study Design." The dose delivered invivo is related to the effective amount determined in vitro. Forexample, if sputum is successfully solubilized in vitro by the amountsexemplified herein (i.e., 2-10 μg/ml), a thousand-fold increase over thein vitro dose would be administered (i.e., 2-10 mg/ml). Of course, itwould be understood that the amounts and regimens for the administrationof actin-binding compounds can be determined readily by those ofordinary skill in the art of treating respiratory disorders. Generally,the dosage of actin-binding compound treatment will vary depending uponconsiderations such as the type of the actin-binding compound employed,the age of the subject, the health of the subject, the severity of thedisease, the kind of concurrent treatment, the extent of tissue damage,the gender of the patient, the duration of the symptoms,counterindications (if any), and other variables understood as needingadjustment by the individual physician. The correct effective dose couldroutinely be determined by monitoring the airway contents by aspirationor as sputum.

Substantially Free of Natural Contaminants.

A material is said to be "substantially free of natural contaminants" ifit has been substantially purified from materials with which it isnormally and naturally found before such purification. Examples ofnatural contaminants with which actin-binding compounds might beassociated are: non-actin-binding peptides, carbohydrates, glycosylatedpeptides, lipids, membranes, etc. A material is said to be substantiallyfree of natural contaminants if those contaminants normally andnaturally found with the substance in vivo or in vitro are substantiallyabsent from a sample of the material. By "substantially absent" is meantthat such contaminants are either completely absent or are present atsuch low concentrations that their presence (1) does not interfere withthe desired therapeutic effect of the active agent (herein theactin-binding compound) in the preparation when such preparation isadministered to an animal and (2) does not harm the animal as the resultof the administration of such preparation.

Administration.

The term "administration" is meant to include introduction ofactin-binding compounds into the respiratory tract of an animal by anyappropriate means known to the medical art, including, but not limitedto inhalation of an aerosolized compound, installation by bronchoscopy,and intravenous infusion.

The actin-binding compounds of the present invention may beco-administered with DNase or one actin binding compound may beco-administered with one or more distinct actin-binding compounds. Bythe term "co-administer" is intended that each of at least two compoundsbe administered during the time frame wherein the respective periods ofbiological activity overlap. Thus, the term includes sequential as wellas coextensive administration of the compounds of the present inventionwith each other or with DNase I.

Pharmaceutically Acceptable Salt.

The term "pharmaceutically acceptable salt" is intended to include saltsof the actin-binding compounds of the invention. Such salts can beformed from pharmaceutically acceptable acids or bases, such as, forexample, acids such as sulfuric, hydrochloric, nitric, phosphoric, etc.,or bases such as alkali or alkaline earth metal hydroxides, ammoniumhydroxides, alkyl ammonium hydroxides, etc.

Pharmaceutically Acceptable Vehicle.

The term "pharmaceutically acceptable vehicle" is intended to includesolvents, carriers, diluents, and the like, which are utilized asadditives to preparations of the actin-binding compounds of theinvention so as to provide a carrier or adjuvant for the administrationof such compounds.

Treatment.

The term "treatment" or "treating" is intended to include theadministration of actin-binding compounds to a subject for purposeswhich may include prophylaxis, amelioration, prevention or cure.

Fragment.

The term "fragment" is meant to include any portion of a molecule whichprovides a segment of an actin-binding compound which is capable ofbinding actin monomers and/or severing filaments; the term is meant toinclude actin-binding fragments which are made from any source, such as,for example, from naturally-occurring peptide sequences, synthetic orchemically-synthesized peptide sequences, and genetically engineeredpeptide sequences. Further, if such fragment is a peptide, a fragment ofa peptide of such actin-binding protein is meant to include to anyvariant of the actin-binding protein.

Variant.

A "variant" is meant to refer to a compound substantially similar instructure and biological activity to either the native compound, or to afragment thereof.

The biological activity of the compounds of the invention is theirability to bind actin and modify it into a form which is less toxic toan animal than unmodified actin. Such modification may be the result ofthe binding of the compounds per se or the result of a chemical orenzymatic reaction which results from such binding.

Functional Derivative.

A "functional derivative" of an attic-binding compound is a derivativewhich possesses a biological activity that is substantially similar tothe biological activity of the actin-binding compound. By "substantiallysimilar" is meant activity which is quantitatively different butqualitatively the same. For example, a functional derivative of anactin-binding protein of the invention would contain the same amino acidback as an actin-binding protein but also contains other modificationssuch as post-translational modifications such as, for example, boundphospholipids, or covalently linked carbohydrate, depending on thenecessity of such modifications for the performance of the diagnosticassay or therapeutic treatment. As used herein, the term is also meantto include a chemical derivative of an actin-binding compound. Suchderivatives may improve the compound's solubility, absorption,biological half life, etc. The derivatives may also decrease thetoxicity of the molecule, or eliminate or attenuate any undesirable sideeffect of the molecule, etc. Derivatives and specifically, chemicalmoieties capable of mediating such effects are disclosed in Remington'sPharmaceutical Sciences (1980). Procedures for coupling such moieties toa molecule are well known in the art. The term "functional derivative"is intended to include the "fragments," "variants," "analogues," or"chemical derivatives" of a molecule.

Analog.

An "analog" of the actin-binding compounds of the invention is meant torefer to a compounds substantially similar in function to either thenative actin-binding compound or to a fragment thereof. For example, ananalog of an actin-binding protein is a protein which does not have thesame amino acid sequence as an actin-binding protein but which issufficiently homologous to an actin-binding protein so as to retain thebiological activity of such actin-binding protein.

The particular actin-binding molecules that are the subject of themethods of the invention are purified native and recombinantactin-binding proteins, and other non-proteinaceous actin-bindingmolecules, and biologically-active fragments thereof, which arecharacterized by the presence of unique actin binding domains whichpossess the biological activity of being able to sequester actin in amonomeric form or rapidly to desegregate or depolymerize actin filamentsor to cover sites on free actin that are toxic to host cells. Individualactin-binding domains possessing this biological activity may also beproduced by synthetic, enzymatic, proteolytic, chemical or recombinantDNA methods.

In a preferred embodiment, gelsolin, DBP, or actin-binding fragmentsthereof, or, a combination of gelsolin and DBP and/or actin-bindingfragments thereof, are provided to the subject in need of treatment.Other actin-binding proteins reasonably expected to be effective for thepurposes of the invention include β₄ thymosin and ASP-56.

Preparations of the actin-binding proteins of the invention forparenteral administration include sterile aqueous or non-aqueoussolvents, suspensions and emulsions. Examples of non-aqueous solventsare propylene glycol, polyethylene glycol, vegetable oil, fish oil, andinjectable organic esters. Aqueous carriers include water, water-alcoholsolutions, emulsions or suspensions, including saline and bufferedmedical parenteral vehicles including sodium chloride solution, Ringer'sdextrose solution, dextrose plus sodium chloride solution, Ringer'ssolution containing lactose, or fixed oils. Intravenous vehicles includefluid and nutrient replenishers, electrolyte replenishers, such as thosebased upon Ringer's dextrose and the like.

The actin-binding proteins of the invention may also be administered bymeans of pumps, or in sustained-release form, especially, when theprimary injury is prolonged or delayed rather an acute.

Administration in a sustained-release form is more convenient for thepatient when repeated injections for prolonged periods of time areindicated. For example, it is desirable to administer the actin-bindingproteins of the invention in a sustained-release form when the methodsof the invention are being used to treat a genetic or chronic diseasebased upon an actin-related disorder so as to maximize the comfort ofthe patient.

The actin-binding proteins of the invention can be employed in dosageforms such as tablets, capsules, powder packets, or liquid solutions fororal administration if the biological activity of the protein is notdestroyed by the digestive process and if the characteristics of thecompound allow it to be absorbed across the intestinal tissue.

The pharmaceutical compositions of the present invention aremanufactured in a manner which is in itself know, for example, by meansof conventional mixing, granulating, dragee-making, dissolving,lyophilizing or similar processes. The compositions of the presentinvention, in and of themselves, find utility in the control ofactin-induced physiological damage, be it chronic or acute. Thecompositions of the invention direct the body's own mechanisms fordealing with excess actin in the bloodstream or extracellular tissues toits maximum potential. In intravenous dosage form, the compositions ofthe present invention have a sufficiently rapid onset of action to beuseful in the acute management of potential tissue damage.

Actin-binding proteins which are substantially free of naturalcontaminants can be isolated and purified from their natural orrecombinant sources in accordance with conventional conditions andtechniques in the art previously used to isolate such proteins, such asextraction, precipitation, chromatography, affinity chromatography,electrophoresis, or the like.

One of skill in the art can identify the actin-binding domain(s) of anactin-binding compound using techniques known in the art, without undueexperimentation, and such domains are preferred in the methods of theinvention. For example, derivatives of the native actin-bindingproteins, or, derivatives of recombinantly produced actin-bindingproteins, can be made by proteolytic cleavage of the full-lengthactin-binding protein with common proteases, such as, for example,trypsin, chymotrypsin, and subtilisin. Affinity chromatography withactin-derivatized resins may be used to assay such fragments for theiractin-binding ability.

When identification of compounds or fragments thereof which possessactin-severing activity is desired, such compounds or fragments can alsobe identified using techniques known in the art, for example, byfollowing the rate of depolymerization of pyrene-labeled F-actin.

Further, such fragments may be identified by their homology to otherknown actin-binding or actin-severing domains wherein it may bepredicted that function will follow homology. For example, it is knownthat severin, gelsolin and villin, and especially amino acid residues40-351 in severin and amino acid residues 63-383 in gelsolin, showextensive homology in the domain responsible for F-actin severingactivity.

The N-terminal half of gelsolin, for example, an N-terminal trypticfragment known as CT45, is capable of severing F-actin and contains twoactin binding sites. Efficacious amounts of CT45 which are substantiallyfree of natural contaminants can be administered to a patient. One ofthese sites resides in a chymotryptic fragment, CT15N (human gelsolinresidues 24-150), which binds the ends of actin monomers and filamentswith high affinity; the other site is contained in the adjacent fragmentCT28N (residues 151-406), which binds to the side of F-actin in apolyphosphoinositide-regulated manner. Neither of the fragments severactin filaments by themselves. The smallest gelsolin polypeptide whichis capable of severing F-actin encompasses residues 25-165 of plasmagelsolin.

Further, compounds such as actin-binding proteins are highly conservedamong species and can be easily isolated in large quantities fromnonhuman bovine, porcine) plasma and/or muscle tissues and fragments bethese proteins can be chemically or enzymatically prepared by techniqueswell-known in the art. Thus such actin-binding compounds can beadministered to a subject in need of the therapeutic methods of theinvention without provoking a severe immune response.

All references cited in this application are incorporated herein byreference. Having now generally described the invention, the followingexamples further describe the materials and methods used in carrying outthe invention. The examples are not intended to limit the invention inany manner.

EXAMPLES Example 1

Specimens of expectorated sputum from patients with cystic fibrosis,some of whom had received aerosolized DNase I, were thawed and separatedinto sections. The procedure described by Shak et al. (Proc. Natl. Acad.Sci. USA 87:9188-9192 (1990)) for determining the effect of DNase I onsputum consistency was followed, except that instead of adding DNase I,purified plasma gelsolin was added. This protein non-covalently seversactin polymers. A recombinant gelsolin fragment produced in E. coli andencompassing amino acid residues 1-260 of gelsolin ("gelsolin 260"),capable also of fragmenting actin filaments, was also used. Theseproteins, which have no known effects on DNA, essentially gave the sameresults described by Shak et al., (Proc. Nail. Acad. Sci. USA87:9188-9192 (1990)) in the pourability test for cystic fibrosis sputum.The gelsolin fragment was more effective than gelsolin, although it wasadded at a three-fold higher concentration (Table 1).

                  TABLE 1                                                         ______________________________________                                        Sputum samples of about 150 mg were divided by cutting with a razor           blade and placed in test tubes containing the indicated additives in 50       mL                                                                            volumes. Samples were incubated at 37° C. in test tubes which          were                                                                          inverted at the time intervals shown in the table, and the presence           and extent of movement noted of sputum following a tap on the side of         the                                                                           tube; 0 = no movement; Tr = <10% of the sputum moved down the side            of the inverted tube; 1+ = 10-20% of the sputum moved; 2+ = 20-50%            of the sputum moved, 3+ = >50% of the sputum moved; 4 + = all of the          sputum moved.                                                                 Additive       0 min  15 min    30 min                                                                              60 min                                  ______________________________________                                        0.15 M NaCl    0      Tr        Tr    Tr                                      +0.5 mM gelsolin                                                                             0      2+        3+    4+                                      +5 mM gelsolin fragment                                                                      0      3+        4+    4+                                      ______________________________________                                    

The experiments were repeated with additional samples of sputum, andgave identical results. Boiled gelsolin fragment was inactive.

Example 2

Sputum samples were studied with a more formal rheological assayinvolving a torsion pendulum. As shown in FIG. 1A, cystic fibrosissputum was very rigid and elastic, as indicated by the high frequencyoscillations induced by a transient stress, from which an elasticmodulus (G') of could be calculated. Addition of gelsolin (1B) andgelsolin fragment (1C) reduced the frequency of the oscillations,lowering the moduli 3- and 10-fold respectively. Again, the fragment,present in higher concentration, was more effective than gelsolin. Thestrain response (known as "creep") of sputum to a steady stress showedthe inherent stiffness or poor compliance of cystic fibrosis sputum,whereas gelsolin and gelsolin fragment, again in a dose-response manner,increased the creep compliance. All samples, however, recovered theiroriginal positions following the removal of the stress, indicating thatcoherent polymers, possibly mucopolysaccharides and DNA, remained in thegels.

Example 3

Rhodamine phalloidin, which binds to polymeric actin, was added tocystic fibrosis sputum specimens which were then observed in the phasecontrast and fluorescence microscopes. The samples contained cellulardebris, the presumed source of DNA and actin, and were brightlyfluorescent. Untreated and gelsolin-fragment-treated sputum plugs werediluted in 2.5 ml of 0.15 M NaCl solution and centrifuged. Theabsorbance at 280 nm was determined as an indication of how much proteinwas released from the sputum gels. The results are shown in Table 2 andshow that gelsolin and the 260 kDa fragment released protein from thesputum plugs.

                  TABLE 2                                                         ______________________________________                                        Sample            0D @ 1 = 280 nm (0D)                                        ______________________________________                                        Sputum alone      0.015                                                       Sputum + 1.5 mM gelsolin                                                                        0.249                                                       Sputum + 2.1 mM 260 fragment                                                                    0.247                                                       ______________________________________                                    

Analysis of Protein Released from Cystic Fibrosis Sputum Gels Incubatedwith Gelsolin.

Samples of 50 μl from the supernatant solutions on which the opticaldensities had been determined were added to an equal volume of sodiumdodecyl sulfate- and β-mercaptoethanol-containing buffer solution, andpolypeptides in this mixture were resolved by polyacrylamide gelelectrophoresis. The gel was stained with Coomassie blue. The gel showedthat the gelsolin- and gelsolin fragment-containing solutions containedmany different proteins and large amounts of three proteins, includingone co-migrating with actin used as a molecular weight standard, thanwith the control supernatant.

Anti-Actin Antibody Immunoblot Study of Cystic Fibrosis Sputum.

Duplicates of cystic fibrosis sputum from two different patients weresuspended in an equal volume of 0.15 M sodium chloride 20 mM Tris-HCl,pH 7.0, and homogenized. 50 μL of the material was added to an equalvolume of SDS gel buffer and resolved by electrophoresis on apolyacrylamide gel. The gel polypeptides were transferred tonitrocellulose and the actin band identified with an anti-actinantibody. Bands were seen in the lanes containing the sputum. Thisresult confirms that actin is present in cystic fibrosis sputum.

Example 4

Solubilization of Purulent Sputum by Actin-Binding Proteins.

Samples of fresh sputum from CF patients were obtained and tested withina few hours of collection. In this test, commercial bovine DNase I wascompared directly with purified plasma gelsolin in the pourability assay(Table 3):

                  TABLE 3                                                         ______________________________________                                                 Gelsolin   DNase I                                                            Concentration, μg/ml                                              Time of incubation                                                            at 37° C.                                                                         2     5        10  2      5   10                                   ______________________________________                                        1     min      0     0      3+  0      0   0                                  3     min      0     Tr     3+  0      0   Tr                                 5     min      Tr    2+     4+  Tr     Tr  Tr                                 10    min      Tr    2+     4+  Tr     Tr  2+                                 15    min      Tr    2+     4+  Tr     1+  3+                                 ______________________________________                                    

Since the molecular weight of DNase I is 31,000 and that of gelsolin,84,000, gelsolin is considerably more effective on a weight basis. Also,the rapid onset of action is consistent with a stoichiometric actionexpected for gelsolin, whereas the slower onset for DNase is moreconsistent with depolymerization by end loss of monomers rather thanfragmentation of actin polymers or enzymatic action on DNA.

Example 5

Synergy Between DNase I and Gelsolin; Concentration-Dependent Release ofProteins.

A protein release experiment was done that showedconcentration-dependent dissolution of sputum samples from three cysticfibrosis patients. Sputum samples of about equivalent volume weresuspended in 0.5 ml of a 0.15M NaCl solution containing purified plasmagelsolin concentrations of approximately 2.0 μg/ml, 4 μg/ml, 7 μg/ml,and 21 μg/ml. After incubation at 37° C. for 30 minutes, the sampleswere centrifuged and the optical density (λ=280 nm) of the supernatantsolutions were determined. On a relative scale, the A₂₈₀ readings wereas follows: 2 μg/ml: 0.25; 4 μg/ml: 1.30; 7 μg/ml: 1.86; 21 μg/ml: 180.The A₂₈₀ after 4 μg/ml DNase I was approximately 0.5. The A₂₈₀ after 4μg/ml DNase I plus 2 μg/ml gelsolin was approximately 1.3. Gelsolinproduced more dissolution expected at a low dose in the presence of abasally ineffective DNase I concentration.

Now having fully described this invention, it will be understood bythose with skill in the art that the scope may be performed within awide and equivalent range of condition, parameters, and the like,without affecting the spirit or scope of the invention or of anyembodiment thereof.

What is claimed is:
 1. A method for solubilizing the purulent airwaycontents of a subject comprising the step of administering anefficacious level of at least one actin-binding compound, other thanDNase I, into the respiratory tract of said subject, wherein saidactin-binding compound sequesters actin monomers, severs actinfilaments, or prevents or reduces the polymerization of actin.
 2. Themethod according to claim 1, wherein DNase I is co-administered to saidsubject.
 3. The method according to claim 1, wherein said purulentairway contents are associated with cystic fibrosis.
 4. The methodaccording to claim 1, wherein said purulent airway contents areassociated with chronic bronchitis.
 5. The method according to claim 1,wherein said purulent airway contents are associated with chronicpurulent sinusitis.
 6. The method according to claim 1, wherein saidpurulent airway contents are associated with bronchopneumonia.
 7. Amethod for reducing the viscosity of the purulent airway contents of asubject comprising the step of administering an efficacious level of atleast one actin-binding compound, other than DNase I, to said subject,wherein said actin-binding compound sequesters actin monomers, seversactin filaments, or prevents or reduces the polymerization of actin. 8.The method according to claim 7, wherein DNase I is co-administered tosaid subject.
 9. The method according to claim 7, wherein said purulentairway contents are associated with cystic fibrosis.
 10. The methodaccording to claim 7, wherein said purulent airway contents areassociated with chronic bronchitis.
 11. The method according to claim 7,wherein said purulent airway contents are associated with chronicpurulent sinusitis.
 12. The method according to clam 7, wherein saidpurulent airway contents are associated with bronchopneumonia.
 13. Amethod of treating respiratory tract obstruction in a subject, whereinsaid obstruction is caused by the presence of purulent airway contents,comprising the step of administering an efficacious level of at leastone actin-binding compound, other than DNase I, to said subject, whereinsaid actin-binding compound sequesters actin monomers, severs actinfilaments, or prevents or reduces the polymerization of actin.
 14. Themethod according to claim 13, wherein DNase I is co-administered to saidsubject.
 15. The method according to claim 13, wherein said purulentairway contents are associated with cystic fibrosis.
 16. The methodaccording to claim 13, wherein said purulent airway contents areassociated with chronic bronchitis.
 17. The method according to claim13, wherein said purulent airway contents are associated with chronicpurulent sinusitis.
 18. The method according to claim 13, wherein saidpurulent airway contents are associated with bronchopneumonia.
 19. Themethod according to any one of claims 1, 7, or 13, wherein saidactin-binding compound is gelsolin or an active fragment thereof. 20.The method according to any one of claims 1, 7, or 13, wherein saidactin-binding compound is DBP.
 21. The method according to any one ofclaims 1, 7, 13, wherein said purulent airway contents are associatedwith a pathological respiratory condition selected from the groupconsisting of empyema, cystic fibrosis, chronic bronchitis, mucopurulentor purulent exacerbation of simple mucoid bronchitis, bronchopneumonia,purulent pneumonia, pneumonic-alveolar consolidation, widespreadbronchiolitis, asthma, asthma with asthmatic bronchitis with mucusplugging, acute purulent sinusitis, chronic purulent sinusitis,bronchiectasis, bronchocoele, post-transplantation obliterativebronchiolitis, and allergenic bronchiolitis (fibrosing alveolitus). 22.The method according to any one of claims 1, 7 or 13, wherein oneactin-binding compound is gelsolin or an active fragment thereof andanother actin-binding compound is DBP.